Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus

Journal of Viral Hepatitis

Volumn 14, Issue SUPPL. 1, 2007, Pages 16-21

  Gerlich, W H ^a   Glebe, D ^a   Schuttler C G ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

Anti HBc; Escape mutants; HBsAg; HBV DNA

Indexed keywords

ALEMTUZUMAB; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; MONOCLONAL ANTIBODY; RITUXIMAB;

BLOOD DONOR; CONFERENCE PAPER; DIAGNOSTIC TEST; DISEASE COURSE; DISEASE MARKER; HEPATITIS B VIRUS; HOST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ORGAN DONOR; PATHOGENESIS; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS PARTICLE; VIRUS REACTIVATION;

DIAGNOSTIC TESTS, ROUTINE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; SENSITIVITY AND SPECIFICITY;

EID: 35448999712     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00912.x     Document Type: Conference Paper

References (43)

1. Kleinman SH, Busch MP. Assessing the impact of HBV NAT on window period reduction and residual risk. J Clin Virol 2006 36 (Suppl. 1 S23 S29.
2. Yugi H, Mizui M, Tanaka J, Yoshizawa H. Hepatitis B virus (HBV) screening strategy to ensure the safety of blood for transfusion through a combination of immunological testing and nucleic acid amplification testing - Japanese experience. J Clin Virol 2006 36 (Suppl. 1 S56 S64.
3. Meisel H, Endres AS, Walter HU, Wend U, Gerlich WH. Transmission of hepatitis B virus 2 months prior to hepatitis surface antigen positivity of donor blood. Transfus Med Hemother 2003 30: 228 231.
4. Furtwängler M, Edwards A, Cyran E, Wend U, Gerlich WH. Nosocomial hepatitis B. Deutsches Ärzteblatt 2006 103: 1084 1087.
5. Erhardt A, Reineke U, Blondin D et al. Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000 31: 716 725.
6. Chulanov VP, Shipulin GA, Schaefer S, Gerlich WH. Kinetics of HBV DNA and HBsAg in acute hepatitis B patients with and without coinfection by other hepatitis viruses. J Med Virol 2003 69: 313 323.
7. Burczynska B, Madalinski K, Pawlowska J et al. The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children. J Hepatol 1994 21: 1097 1102.
8. Thomssen R, Gerlich WH, Stamm B. Hepatitis B: its agents and course of infection. Preliminary results of a joint study. Bundesgesundheitsblatt 1978 21: 337 344.
9. Frösner GG, Schomerus H, Wiedmann KH et al. Diagnostic significance of quantitative determination of hepatitis B surface antigen in acute and chronic hepatitis B infection. Eur J Clin Microbiol 1982 1: 52 58.
10. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004 126: 1750 1758.
11. Gerlich WH, Wend U, Glebe D. Quantitative assay of hepatitis B surface antigen in serum or plasma using Laurell electrophoresis. Methods Mol Med 2004 95: 57 63.
12. Gerlich W, Thomssen R. Standardized detection of hepatitis B surface antigen: determination of its serum concentration in weight units per volume. Dev Biol Stand 1975 30: 78 87.
13. Lelie PN, Reesink HW, Niessen J, Brotman B, Prince AM. Inactivation of 10(15) chimpanzee-infectious doses of hepatitis B virus during preparation of a heat-inactivated hepatitis B vaccine. J Med Virol 1987 23: 289 295.
14. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J Virol 1984 52: 396 402.
15. Minegishi K, Yoshikawa A, Kishimoto S et al. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang 2003 84: 287 291.
16. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004 44: 1332 1339.
17. Schaefer S. Hepatitis B virus: significance of genotypes. J Viral Hepat 2005 12: 111 124.
18. Norder H, Courouce AM, Coursaget P et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology 2004 47: 289 309.
19. Courouce AM, Soulier JP. The a(w) subdeterminants. Bibl Haematol 1976 42: 31 41.
20. Levicnik-Stezinar S. Hepatitis B surface antigen escape mutant in a first time blood donor potentially missed by a routine screening assay. Clin Lab 2004 50: 49 51.
21. Koppelman MH, Zaaijer HL. Diversity and origin of hepatitis B virus in Dutch blood donors. J Med Virol 2004 73: 29 32.
22. Uy A, Wunderlich G, Olsen DB, Heermann KH, Gerlich WH, Thomssen R. Genomic variability in the preS1 region and determination of routes of transmission of hepatitis B virus. J Gen Virol 1992 73: 3005 3009.
23. Bozkaya H, Akarca US, Ayola B, Lok AS. High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection. J Hepatol 1997 26: 508 516.
24. Bozkaya H, Ayola B, Lok AS. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic hepatitis B virus infection. Hepatology 1996 24: 32 37.
25. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996 2: 1104 1108.
26. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007 46: 160 170.
27. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004 86: 83 91.
28. Mosley JW, Stevens CE, Aach RD et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995 35: 5 12.
29. Prince AM, Lee DH, Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001 41: 329 332.
30. Burger R, Offergeld R. Testing plasma donations for hepatitis B core antigen (anti-HBc) in order to improve safety of cellular blood components and of quarantined fresh frozen plasma. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2005 48: 698 699.
31. Gerlich WH, Wagner FF, Chudy M et al. HBsAg non-reactive HBV infection in blood doners: transmission and pathogenicity. J Med Virol 2007 in press.
32. Basuni AA, Carman WF. HBV vaccine-escape variants. Methods Mol Med 2004 95: 115 124.
33. Nainan OV, Khristova ML, Byun K et al. Genetic variation of hepatitis B surface antigen coding region among infants with chronic hepatitis B virus infection. J Med Virol 2002 68: 319 327.
34. Ghany MG, Ayola B, Villamil FG et al. Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis. Hepatology 1998 27: 213 222.
35. Glebe D, Urban S, Knoop EV et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005 129: 234 245.
36. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005 79: 616 619.
37. Westhoff TH, Jochimsen F, Schmittel A et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003 102: 1930.
38. Moses SE, Lim ZY, Sudhanva M et al. Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. J Med Virol 2006 78: 1560 1563.
39. Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 2006 78 (Suppl. 1 S66 S70.
40. Ly TD, Servant-Delmas A, Bagot S et al. Sensitivities of four new commercial hepatitis B virus surface antigen (HBsAg) assays in detection of HBsAg mutant forms. J Clin Microbiol 2006 44: 2321 2326.
41. Awerkiew S, Daumer M, Reiser M et al. Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007 38: 83 86.
42. Gärtner BC, Jung W, Welsch C et al. Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. J Clin Virol 2007 38: 146 148.
43. Avettand-Fenoel V, Thabut D, Katlama C, Poynard T, Thibault V. Immune suppression as the etiology of failure to detect anti-HBc antibodies in patients with chronic hepatitis B virus infection. J Clin Microbiol 2006 44: 2250 2253.